MedImmune Ventures, Inc. insider trades: G1 Therapeutics (GTHX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where MedImmune Ventures, Inc. reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 15, 2017 | GTHX | ↓ Sell | 200,000 | $19.75 | $4.0M | Direct | Dec 18, 2017 (3d) |
| Dec 1, 2017 | GTHX | ↓ Sell | 133,906 | $19.75 | $2.6M | Direct | Dec 5, 2017 (4d) |
| Nov 20, 2017 | GTHX | ↓ Sell | 200,000 | $20.01 | $4.0M | Direct | Nov 22, 2017 (2d) |
| May 22, 2017 | GTHX | ↑ Buy | 75,000 | $15.00 | $1.1M | Direct | May 24, 2017 (2d) |
| Jun 30, 2015 | CATB | ↑ Buy | 223,439 | $12.00 | $2.7M | Direct | Jun 30, 2015 (0d) |
| Feb 23, 2015 | ITEK | ↑ Buy | 416,667 | $6.00 | $2.5M | Indirect | Feb 25, 2015 (2d) |
| Apr 1, 2014 | AGTC | ↑ Buy | 75,735 | $12.00 | $909K | Direct | Apr 1, 2014 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About MedImmune Ventures, Inc.'s insider trades
MedImmune Ventures, Inc. is a 10% owner of G1 Therapeutics (GTHX). Since Apr 1, 2014, it has reported 4 open-market purchases worth $7.2M and 3 sales worth $10.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GTHX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.